The PMWC 2021 Genomic Profiling Showcase will provide a 15 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.
Confirmed Presenting Companies:
Dr. William Audeh is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles, where he continues to be a member of the Medical Staff. He became Chief Medical Officer of Agendia, a molecular diagnostics company specializing in breast cancer genomics, in May of 2016. Prior to joining Agendia, in addition to his clinical practice, he served as Director of the Cedars-Sinai Cancer Center, Clinical Chief of the Division of Hematology/Oncology, and Medical Director of the Wasserman Breast Cancer Risk Reduction Program. Dr. Audeh was also a faculty member in the Breast Surgery and Surgical Oncology Fellowships at Cedars-Sinai and was Associate Clinical Professor of Medicine at the UCLA School of Medicine. Dr Audeh obtained his MD degree for the University of Iowa, MS in Genetics from University of Minnesota, and Internal Medicine and Oncology training at Stanford University.
Genomic Profiling Showcase:
From day one, Agendia was founded on the belief we could improve the quality of life for cancer patients everywhere. Today, our genomic tests are achieving this goal with a broad and growing global customer base, including many major hospitals and clinical institutions.
Alif is a pioneer in integrating network science with molecular data to match individual patients with the most effective therapies. Alif and his team have spent the last decade pioneering a network medicine platform – a powerful tool that has the potential to predict patient response to targeted therapies, develop precision diagnostics and repurpose previously approved drugs. A Swedish national with a perspective on global healthcare systems, Alif has led cross-disciplinary teams throughout Asia, Europe, and the Americas - raising over $225M in venture and private equity capital. Alif is an experienced speaker and writer on healthcare topics and was recently featured on The Bio Report podcast (“Bringing Precision Medicine to Autoimmune Disease”), at the BIO International Convention (“Precision Medicine Outside Oncology: One Size Does Not Fit All),” and on Morning Consult (“Addressing Healthcare’s Largest Hidden Cost: Drug Nonresponse”).
Genomic Profiling Showcase:
Scipher Medicine is committed to transforming the way healthcare prioritizes drugs for patients. Our first product, PrismRA, is a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to the world's best-selling drug class: TNF inhibitors.
Bringing Precision Medicine To Autoimmune Disease
In rheumatoid arthritis, only 1 in 3 patients respond to the top biologic therapies. Scipher Medicine’s PrismRA test identifies patients who are less likely to respond to TNFi therapies, allowing patients to optimize drug class selection prior to treatment.